$VRXA

Veraxa Biotech AG - Post de-SPAC

Veraxa is an oncology-focused biotechnology and clinical drug development company based in Zurich, Switzerland. Its pipeline includes VX-A901, an antibody that has completed a Phase I clinical trial for the treatment of acute myeloid leukemia. Veraxa also has the BiTAC-TCE platform, derived from the in-licensed Hemibody platform. Veraxa’s technologies include Hitmaster and microfluidics-based antibody screening, genetic code expansion, and click chemistry for antibody drug conjugation. Its wholly owned subsidiary, VERAXA Biotech GmbH, conducts all of its research and development activities in Heidelberg, Germany. Veraxa has raised capital to support the advancement of its technologies and programs.

No enriched coverage for $VRXA in the last 7 days.

$43K
—
Gruninger Marc
0%
See all $VRXA insider activity →
Low

VERAXA Biotech Expands Human-Relevant Testing to Advance BiTAC Cancer Therapies

VERAXA Biotech (VRXA) is expanding human-relevant preclinical testing for its cancer therapies, using 3D tumor models and patient-derived samples. Its lead BiTAC T-cell engager showed potent tumor-cell killing in 10 lung cancer models, requiring fewer mice. The approach aims to accelerate drug development and reduce animal testing. According to the company, this could lower failure rates and costs, aligning with regulatory trends.

Gruninger Marc purchased $10K of VRXA

Gruninger Marc purchased 10,000 shares of Veraxa Biotech AG - Post de-SPAC (VRXA) at an average of $1.00 ($0.98–$1.00) across 2 trades over 2026-10-27 to 2026-10-28.

VRXA sentiment & insider activity

Recent VRXA coverage spans financial news, insider activity and technology.

In the last 30 days, VRXA insiders filed 3 SEC Form 4 transactions — 3 purchases ($43K) and no sales. The most active reporter was Gruninger Marc with 2 filings.

What's driving VRXA

AlphAI scores every news story that mentions VRXA with an AI model for sentiment and relevance, and aggregates insider trades from Veraxa Biotech AG - Post de-SPAC's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $VRXA

Score

VERAXA Biotech Expands Human-Relevant Testing to Advance BiTAC Cancer Therapies

VERAXA Biotech (VRXA) is expanding human-relevant preclinical testing for its cancer therapies, using 3D tumor models and patient-derived samples. Its lead BiTAC T-cell engager showed potent tumor-cell killing in 10 lung cancer models, requiring fewer mice. The approach aims to accelerate drug development and reduce animal testing. According to the company, this could lower failure rates and costs, aligning with regulatory trends.

Veraxa Biotech AG: VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC-ADC Technology at World ADC Congress

VERAXA Biotech AG (NASDAQ: VRXA) presented in vivo proof-of-concept data for its BiTAC-ADC technology at the World ADC Congress. The data showed significant tumor regression in a breast cancer model with a single dose, while maintaining safety. The company highlights the potential for safer cancer treatments with comparable efficacy to conventional ADCs.

Veraxa Biotech stock gains on FDA-aligned testing strategy

Veraxa Biotech AG (VRXA) shares rose 3.7% premarket after announcing an FDA-aligned strategy to reduce animal testing in preclinical programs. The approach uses New Approach Methodologies, aiming to cut costs and timelines. The company presented data on its BiTAC-TCE program at AACR 2026, showing targeted cancer cell killing with minimal activity against non-expressed targets.

Veraxa Biotech AG: VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy

VERAXA Biotech AG (VRXA) announced its adoption of FDA-aligned New Approach Methodologies (NAMs) in its R&D strategy, aiming to accelerate its BiTAC oncology pipeline and reduce animal testing. The company presented initial data at the AACR Annual Meeting 2026, showing promising results for its BiTAC-TCE program. VERAXA's NAMs include cell-based assays, organ-on-chip systems, and computational modeling, which the company believes will reduce development costs and timelines.

VERAXA Biotech (NASDAQ: VRXA) Builds Oncology Pipeline Around BiTAC Platform, Public-Market Story Enters Next Phase

VERAXA Biotech (VRXA) is advancing its oncology pipeline using its BiTAC platform, which targets cancer cells with a dual-component approach. The company went public on NASDAQ in June 2026 via a merger with Voyager Acquisition Corp. and has since reported early preclinical data for its BiTAC-TCE and BiTAC-ADC approaches. Recent executive appointments include a new CFO and chief scientific officer.

Related tickers